Clinical Trials in San Luis, Argentina

5 recruiting

Showing 111 of 11 trials

Recruiting
Phase 3

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

Cardiovascular Disease and Lipoprotein(a)
Novartis Pharmaceuticals5,700 enrolled492 locationsNCT07517263
Recruiting

Fabry Disease Registry & Pregnancy Sub-registry

Fabry Disease
Genzyme, a Sanofi Company9,000 enrolled283 locationsNCT00196742
Recruiting

Organ Dysfunction Score for Obstetric Patients

SepsisPregnancyPostpartum+2 more
Daniela Vasquez130 enrolled18 locationsNCT07068022
Recruiting
Phase 3

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

Chronic Kidney DiseaseProteinuria
Bayer219 enrolled164 locationsNCT05196035
Recruiting
Phase 2

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

Lupus Nephritis
Novartis Pharmaceuticals240 enrolled103 locationsNCT05268289
Recruiting
Phase 3

A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

Chronic Kidney DiseaseProteinuriaChildren
Bayer100 enrolled178 locationsNCT05457283
Recruiting
Phase 2

BAY3401016; Biomarker Study Alport

Alport Syndrome
Bayer60 enrolled60 locationsNCT07211685
Recruiting
Phase 3

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

Atrial Fibrillation (AF)
Anthos Therapeutics, Inc.1,900 enrolled734 locationsNCT05712200
Recruiting
Phase 3

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

Pulmonary Hypertension Associated With HFpEF
Tenax Therapeutics, Inc.540 enrolled92 locationsNCT07288398
Recruiting
Phase 3

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

Focal Onset Seizures
Xenon Pharmaceuticals Inc.360 enrolled94 locationsNCT05716100
Recruiting
Phase 3

Efficacy of INM004 in Children With STEC-HUS

Hemolytic-Uremic Syndrome
Inmunova S.A.220 enrolled52 locationsNCT06389474